UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________
Form 6-K
__________________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
February 10, 2016
__________________________
Lombard Medical, Inc.
(Exact Name of Registrant as Specified in Its Charter)
__________________________
N/A
(Translation of Registrant’s Name into English)
__________________________
| Cayman Islands | 3841 | Not applicable |
| (State or Other Jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer |
| Incorporation or Organization) | Classification Code Number) | Identification Number) |
6440 Oak Canyon
Suite 200
Irvine, CA 92618
+866-790-1447
(Address, Including ZIP Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
__________________________
Lombard Medical, Inc.
6440 Oak Canyon
Suite 200
Irvine, CA 92618
(Name, Address of Agent for Service)
__________________________
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-FX Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):o
On February 5, 2016, and February 7, 2016, three Officers of Lombard Medical, Inc. (the “Company”) purchased ordinary shares of the Company. On February 5, 2016, the Company’s President, US Commercial Operations, Michael Gioffredi purchased 12,000 shares in open market transactions at an average price of $0.76, and Chief Technology Officer Peter Phillips purchased 5,600 shares in open market transactions at an average price of $0.70. On February 7, 2016, VP, Clinical and Regulatory, Linda D’Abate purchased 6,000 shares in open market transactions at an average price of $0.76.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Lombard Medical, Inc. | ||
| By: | /s/ William J. Kullback | |
| William J. Kullback | ||
| Chief Financial Officer | ||
Date: February 10, 2016